EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Potential Hepatoprotective Effects of Adenosine Triphosphate Against Olaparib-Induced Oxidative Liver Injury: An Experimental Rat Model

Ahmed Ramiz Baykan iD, Serkan Cerrah iD, Emine Kartal Baykan iD, Serdar Tanas iD, Bulent Yavuzer iD, Gulce Naz Yazici, Mehmet Kuzucu, Durdu Altuner, Halis Suleyman iD

Drug Design, Development and Therapy · 2026-06 · Volume 20 · 1-17

DOI: 10.2147/dddt.s613667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-06. Verfasst von Ahmed Ramiz Baykan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Erzurum City Hospital, Erzurum, Turkey. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Adenosine Triphosphate, Oxidative Stress. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Olaparib, a clinically established poly (ADP-ribose) polymerase (PARP) inhibitor widely used in oncology, has significantly improved outcomes in several malignancies. However, increasing evidence indicates that olaparib may induce hepatocellular injury through mechanisms involving oxidative stress, inflammation, and mitochondrial dysfunction. Adenosine triphosphate (ATP), a key regulator of cellular bioenergetics and redox homeostasis, may confer protection against oxidative tissue injury. This study investigated the hepatoprotective effects of ATP against olaparib-induced oxidative liver damage in rats and compared its efficacy with melatonin.

Methods

Twenty-four male albino Wistar rats were randomly assigned to four experimental groups (n = 6): healthy control (HG), olaparib-treated (OLP), ATP plus olaparib (ATOL), and melatonin plus olaparib (MLOL). Olaparib was administered at a dose of 100 mg/kg orally twice daily, whereas ATP (5 mg/kg, intraperitoneally) and melatonin (10 mg/kg, orally) were administered once daily. The treatments were administered for 14 consecutive days. Hepatic oxidative and inflammatory status was assessed by measuring malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), catalase (CAT), interleukin-6 (IL-6) and ATP levels in liver tissue. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were measured as biochemical indicators of hepatocellular injury. Liver tissues were also examined histopathologically.

Results

Olaparib administration significantly increased hepatic MDA and IL-6 levels together with serum ALT and AST activities, while significantly reducing hepatic tGSH and ATP levels and SOD and CAT activities compared with the healthy group ( p < 0.001). Both ATP and melatonin significantly attenuated these alterations ( p < 0.001). Notably, ATP demonstrated a more pronounced protective effect than melatonin, particularly in suppressing aminotransferase elevations and improving histopathological liver architecture.

Conclusion

ATP significantly alleviates olaparib-induced hepatotoxicity by attenuating oxidative stress, suppressing inflammatory responses, restoring antioxidant defense mechanisms and significantly replenishing depleted hepatic ATP levels. These findings suggest that ATP may represent a promising therapeutic strategy for preventing PARP inhibitor-associated drug-induced liver injury. The diagram illustrates a study on olaparib-induced hepatotoxicity. Olaparib is administered orally twice daily, leading to hepatotoxicity in a rat model. Adenosine triphosphate is given intraperitoneally once daily and melatonin is given orally once daily. The study includes four groups: Healthy (n=6), Olaparib-alone (100 mg/kg) (n=6), ATP (5 mg/kg) plus Olaparib (100 mg/kg) (n=6) and Melatonin (10 mg/kg) plus Olaparib (100 mg/kg) (n=6). Liver tissue analysis includes measurements of malondialdehyde, total glutathione, superoxide dismutase, catalase, interleukin 6 and adenosine triphosphate for all groups (n=6). Histopathology is performed for all groups (n=6). Blood serum analysis includes alanine transaminase and aspartate transaminase for all groups (n=6).Study: olaparib hepatotoxicity, ATP/melatonin treatments, liver tissue & serum analysis. Keywords: olaparib, adenosine triphosphate, drug-induced liver injury, PARP inhibitors, oxidative stress, interleukin-6, alanine aminotransferase, aspartate aminotransferase, melatonin, rats

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesAdenosine TriphosphateOxidative StressChemical and Drug Induced Liver InjuryDisease Models, AnimalAnimalsRats, WistarMaleRatsMelatoninLiverDose-Response Relationship, DrugPoly(ADP-ribose) Polymerase InhibitorsAntioxidants

Stichwörter der Autor:innen

PARP inhibitorsadenosine triphosphatealanine aminotransferaseaspartate aminotransferasedrug-induced liver injuryinterleukin-6melatoninolapariboxidative stressrats

Substanzen

PhthalazinesPiperazinesolaparibAdenosine TriphosphateMelatoninPoly(ADP-ribose) Polymerase InhibitorsAntioxidants

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Erzurum City Hospital, Erzurum, Turkey.
  • Division of Gastroenterology, Department of Internal Medicine, Erzurum Regional Training and Research Hospital, University of Health Sciences, Erzurum, Turkey.
  • Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Erzurum Regional Training and Research Hospital, University of Health Sciences, Erzurum, Turkey.
  • Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey.
  • Department of Histology and Embryology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey.
  • Department of Molecular Biology, Faculty of Arts and Sciences, Erzincan Binali Yıldırım University, Erzincan, Turkey.

ORCID-Profile: Ahmed Ramiz Baykan, Serkan Cerrah, Emine Kartal Baykan, Serdar Tanas, Bulent Yavuzer, Halis Suleyman

Zitieren

APA

Baykan, A. R., Cerrah, S., Kartal Baykan, E., Tanas, S., Yavuzer, B., Yazici, G. N., Kuzucu, M., Altuner, D., & Suleyman, H. (2026). Potential Hepatoprotective Effects of Adenosine Triphosphate Against Olaparib-Induced Oxidative Liver Injury: An Experimental Rat Model. Drug Design, Development and Therapy, Volume 20, 1-17. https://doi.org/10.2147/dddt.s613667

Vancouver

Baykan AR, Cerrah S, Kartal Baykan E, Tanas S, Yavuzer B, Yazici GN, et al. Potential Hepatoprotective Effects of Adenosine Triphosphate Against Olaparib-Induced Oxidative Liver Injury: An Experimental Rat Model. Drug Design, Development and Therapy. 2026;Volume 20:1-17. doi:10.2147/dddt.s613667

BibTeX
@article{Baykan2026,
  author = {Baykan, Ahmed Ramiz and Cerrah, Serkan and Kartal Baykan, Emine and Tanas, Serdar and Yavuzer, Bulent and Yazici, Gulce Naz and Kuzucu, Mehmet and Altuner, Durdu and Suleyman, Halis},
  title = {Potential Hepatoprotective Effects of Adenosine Triphosphate Against Olaparib-Induced Oxidative Liver Injury: An Experimental Rat Model},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--17},
  doi = {10.2147/dddt.s613667}
}
Kostenlos starten →